Clinical Trial Update: Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of WID-RGC20 (Cariprazine) in patients with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• WID-RGC20 (Cariprazine) (cariprazine)

Snippet

Sponsor: Whanin Pharmaceutical Company | Conditions: Schizophrenia | Phase 3 | Status: UNKNOWN